Comparative Study of Efficacy of Topical Olopatadine (0.1%), Bepotastine (1.5%) and Alcaftadine (0.25%) in Mild to Moderate Allergic Conjunctivitis

Description

Abstract (English)

Abstract
Aim: The aim of the present study was to compare the efficacy and safety of Alcaftadine 0.25%, Olopatadine
hydrochloride 0.1%, and Bepotastine besilate 1.5% ophthalmic solutions in the treatment of allergic
conjunctivitis.
Methods: A prospective study was conducted on 210 patients of allergic conjunctivitis visiting Department of
Ophthalmology of a tertiary care hospital in south Bihar after random selection. Randomly generated treatment
regimens were sealed within opaque envelopes and were allocated to the patients after obtaining their informed
consent. A total of 210 patients were enrolled in this study. All the cases were divided into three groups (Group
A, B and C).
Results: Mean age of group A patients was 27.33 ± 10.30 years, group B patients was 29.61 ± 9.31 years and
group C was 28.82 ± 9.81 years. There was male predominance in all the three groups. At day 1, Total ocular
symptom score (TOSS) of group A, B and C was 7.49 ± 2.48, 7.63 ± 2.28 and 7.56 ± 2.36 respectively. As
compared to 1st visit and last visit (14 days) followed up TOSS was greatly reduced in group A and C than
group B cases. Conjunctival hyperaemia had reduced in all the treatment groups but there was a significant
reduction in Alcaftadine and Bepotastine treatment groups at 14th day compared to olopatadine group (p =
0.0001). In this present study, degree of hyperaemia was highly significantly decreases in 4th visit as compared
the 1st visit in all group of patients. Hyperaemia in group A and C patients were greatly reduced as compared to
group B patients.
Conclusion: All three topical ophthalmic medications used in the study are safe and effective in the treatment of
allergic conjunctivitis. However, Bepotastine and Alcaftadine appear to outweigh Olopatadine in resolving the
symptoms of allergic conjunctivitis